Cardiac biomarkers are proteins found in the blood that can help diagnose and monitor different heart conditions. Cardiac troponin and CK-MB are among the most commonly used biomarkers for detecting cardiac injury and assessing the effectiveness of treatment. The global cardiac biomarker market has witnessed significant growth in recent years due to the rising incidence of cardiovascular diseases worldwide and growing emphasis on early diagnosis and screening.
The global Cardiac Biomarkers Market is estimated to be valued at Us$ 9836.55 Mn in 2023 and is expected to exhibit a CAGR Of 6.0% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends driving the cardiac biomarkers market growth is the increasing adoption of high sensitivity troponin tests. Traditionally, troponin tests available in the market had low sensitivity and could only detect significant cardiac injury. However, advancements in assay design have led to development of high sensitivity troponin tests that are able to detect even small amounts of troponin in blood. Compared to conventional troponin tests, high sensitivity troponin assays have demonstrated better diagnostic accuracy for early detection of myocardial injury. Their ability to rule out minor myocardial injury sooner is leading to higher adoption among healthcare providers globally. This shift towards use of more sensitive cardiac biomarker tests is expected to significantly contribute to the revenue growth of the cardiac biomarkers market over the forecast period.
Segment Analysis
The global cardiac biomarkers market is segmented based on product type, application, and end-use. By product type, the cardiac troponin I and T sub-segment dominates the market and is anticipated to continue leading the market during the forecast period. This is because cardiac troponin biomarkers provide accurate and precise diagnosis of acute myocardial infarction and other heart conditions. By application, the myocardial infarction sub-segment holds the largest share of the market. This is owing to the increasing prevalence of myocardial infarction worldwide.
Key Takeaways
The Global Cardiac Biomarkers Market Demand is expected to witness high growth during the forecast period from 2023 to 2030. The market was valued at US$ 9836.55 Mn in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period.
Regional analysis:
North America currently dominates the global cardiac biomarkers market and is expected to continue leading the market during the forecast period. This is attributed to growing geriatric population, rising prevalence of cardiovascular diseases, availability of advanced healthcare facilities, and adoption of advanced cardiac biomarker testing in the region. Asia Pacific is anticipated to be the fastest-growing regional market between 2023 and 2030. This growth is driven by increasing healthcare expenditure, rising awareness regarding cardiac biomarkers, and expansion of private healthcare organizations in various Asia Pacific countries.
Key players operating in the cardiac biomarkers market are Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Randox Laboratories Ltd., Siemens Healthineers, and BioMérieux SA. Abbott Laboratories and F. Hoffmann-La Roche AG currently dominate the global market owing to their robust product portfolio and strong geographical presence across the globe.
Get more insights on this topic :
Check more trending articles on this topic:
